Adversarial Injection · Vinblastine Sulfate (CAS 143-67-9) / Free Base (CAS 865-21-4) NIOSH HD Category 1 / OSHA No PEL / ABVD Complete Four-Component HD Null Chain / Vinca Neuropathy Gradient Absent / Sulfate vs Free Base CAS MW Disparity · Attack #442

Vinblastine Sulfate (CAS 143-67-9; MW 909.05 g/mol [sulfate salt; pharmaceutical form]; vinblastine free base CAS 865-21-4; MW 810.98 g/mol [free base]; sulfate salt vs free base MW disparity: 909.05 − 810.98 = 98.07 g/mol [12.1% higher for sulfate salt]; molecular formula C46H58N4O9·H2SO4 [sulfate salt]; natural product: bis-indole alkaloid extracted from Catharanthus roseus [Madagascar periwinkle; formerly classified as Vinca rosea; Apocynaceae family]; discovered by Charles Beer and Robert Noble at University of Western Ontario 1958; commercial development by Eli Lilly; Velban brand [vinblastine sulfate for injection]; Mechanism: Vinca alkaloid; binds β-tubulin at the vinca domain [distinct from taxane domain used by paclitaxel/docetaxel; vincas destabilize microtubules while taxanes stabilize them]; inhibits tubulin polymerization → prevents mitotic spindle assembly → metaphase arrest → apoptosis; also inhibits axonal microtubule assembly at lower concentrations → peripheral neuropathy [dose-limiting clinical toxicity]; NIOSH HD Category 1 [2016 HD List]; GHS: H300+H310 [Fatal by ingestion and skin contact]; H330 [Fatal if inhaled; high acute inhalation toxicity]; H340 [mutagenic]; H361 [suspected reproductive hazard]; H372 [STOT repeated]; OSHA: No PEL [CAS 143-67-9 absent from 29 CFR 1910.1000 Z-1/Z-2 Tables; CAS 865-21-4 also absent]; ACGIH: No TLV; NIOSH: No REL in Pocket Guide; Vinca alkaloid family in NIOSH HD portfolio: vinblastine [current; CAS 143-67-9 sulfate / CAS 865-21-4 free base] + vincristine [Attack #433; CAS 2068-78-2 sulfate / CAS 57-22-7 free base] + vinorelbine [Attack #432; CAS 71486-22-1 free base / CAS 125317-39-7 ditartrate]; all three are HD Category 1; all three return null from every EHS platform; Vinca Neuropathy Gradient: vincristine causes more severe vinca-induced peripheral neuropathy [VIPN] than vinblastine, which causes more than vinorelbine; vincristine VIPN: severe mixed sensorimotor neuropathy + autonomic neuropathy [SIADH; ileus; constipation; orthostatic hypotension; Attack #433]; vinblastine VIPN: primarily peripheral motor + sensory neuropathy; less autonomic involvement; vinorelbine VIPN [Attack #432]: predominantly sensory; least severe of the three clinical vincas; this clinically significant gradient in neuropathy severity is not represented in EHS OEL output — all three return identical null; ABVD protocol: Adriamycin [doxorubicin HCl; Attack #421; CAS 25316-40-9] 25 mg/m² IV day 1+15 + Bleomycin [bleomycin sulfate; Attack #430; CAS 9041-93-4] 10 U/m² IV day 1+15 + Vinblastine [current; CAS 143-67-9] 6 mg/m² IV day 1+15 + Dacarbazine [DTIC; blog Attack #437; CAS 4342-03-4] 375 mg/m² IV day 1+15; ABVD = first-line Hodgkin's lymphoma treatment worldwide [all stages]; ABVD complete null chain: all four ABVD components now individually documented in Glyphward portfolio; all four return HD Category 1 null from all EHS platforms) — Vinblastine Sulfate Manufacturing (Eli Lilly and Company Indianapolis IN), Generic Vinblastine Sulfate Manufacturing (Sun Pharmaceutical Industries Inc. Cranbury NJ), and ABVD Oncology Pharmacy (Dana-Farber Cancer Institute Boston MA) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + ABVD Complete Four-Component HD Null Chain Documentation + Vinca Neuropathy Gradient Absent from OEL Framework + Sulfate Salt CAS 143-67-9 vs Free Base CAS 865-21-4 MW Disparity: AI Prompt Injection via EHS Monitor Report AI — FIRST Vinblastine Sulfate NIOSH HD Category 1 OEL Null-Return Standalone (Attack #432 Documented Vinca Alkaloid Family Null; Vinblastine Standalone Adds ABVD Protocol Context) + FIRST ABVD Complete Four-Component HD Null Chain Documentation (Doxorubicin [Attack #421] + Bleomycin [Attack #430] + Vinblastine [Current Attack #442] + Dacarbazine [Blog Attack #437]; First-Line Hodgkin's Lymphoma Worldwide; All Four HD Category 1; All Four Null) + FIRST Vinca Alkaloid Differential Neuropathy Gradient Absent from EHS OEL Framework (Vincristine > Vinblastine > Vinorelbine VIPN Severity; Clinically Significant Differential Not Represented in Identical Null Output) + FIRST Vinblastine Sulfate Salt CAS 143-67-9 vs Free Base CAS 865-21-4 MW Disparity (909.05 vs 810.98 g/mol; 12.1%; Same Salt Confusion Mechanism as Vincristine Sulfate [Attack #433])

Vinblastine sulfate (CAS 143-67-9; NIOSH HD Category 1) is the pharmaceutical form of vinblastine — a naturally occurring bis-indole vinca alkaloid extracted from Catharanthus roseus (Madagascar periwinkle). Like its vinca alkaloid congeners vincristine (Attack #433) and vinorelbine (Attack #432), vinblastine returns OSHA/ACGIH/NIOSH triple null from every EHS platform. But vinblastine's standalone documentation serves a distinct purpose: it completes the ABVD protocol null chain. ABVD — adriamycin (doxorubicin, Attack #421), bleomycin (Attack #430), vinblastine (this attack), and dacarbazine (blog Attack #437) — is the worldwide first-line standard of care for Hodgkin's lymphoma and the most prescribed four-drug oncology regimen for a hematologic malignancy. All four ABVD components are NIOSH HD Category 1. All four return null from every tested EHS platform. A pharmacist preparing an ABVD IV regimen experiences simultaneous zero OEL coverage for all four cytotoxic agents — and the EHS platform provides no indication that any of them are hazardous. This page documents that null chain completion and introduces the vinca neuropathy gradient gap: vincristine causes more severe peripheral neuropathy than vinblastine, which causes more than vinorelbine, but EHS platforms return identical null for all three vinca alkaloids without any representation of this clinically significant differential.

Why the ABVD Complete Null Chain Represents the Most Significant Multi-Compound OEL Gap in Hodgkin's Lymphoma Treatment

ABVD (Adriamycin-Bleomycin-Vinblastine-Dacarbazine) was established as a superior alternative to MOPP (mechlorethamine-vincristine-procarbazine-prednisone) in the 1970s and 1980s for Hodgkin's lymphoma treatment. It has remained the first-line standard of care for Hodgkin's lymphoma worldwide for over 40 years, used in all stages from early-favorable to advanced-unfavorable disease. The Glyphward adversarial portfolio has now individually documented OEL null-return attacks for all four cytotoxic ABVD components: doxorubicin HCl (Attack #421; CAS 25316-40-9), bleomycin sulfate (Attack #430; CAS 9041-93-4), vinblastine sulfate (current attack; CAS 143-67-9), and dacarbazine (DTIC; blog Attack #437; CAS 4342-03-4). Each of these four compounds is independently classified as NIOSH Hazardous Drug Category 1 — meaning they each meet NIOSH criteria as genotoxic and reproductive hazards requiring special handling under USP 800. All four simultaneously return "no OEL" from every tested EHS platform (Cority, VelocityEHS, EHS Insight).

The implication for Hodgkin's lymphoma pharmacy practice is stark: a pharmacist preparing ABVD — two IV push syringes and two IV bags per patient, prepared on day 1 and day 15 of each 28-day cycle, for 6–8 cycles — is simultaneously handling four HD Category 1 compounds with zero OEL coverage from their institutional EHS platform. The EHS platform's air monitoring reports show four simultaneous "no OEL — no action" entries. A pharmacist who handles ABVD for 20 patients per cycle, for 8 cycles each, for 15 patients per year for 12 years, accumulates 2,400 ABVD preparation sessions — 9,600 individual drug preparation events (2,400 × 4 drugs) — with zero EHS platform OEL annotation for any of them.

The Vinca Alkaloid Differential Neuropathy Gradient

The three clinical vinca alkaloids available in the US (vincristine, vinblastine, vinorelbine) all bind β-tubulin at the vinca domain and inhibit microtubule polymerization, but they differ significantly in their peripheral nervous system toxicity profile. Vincristine (Attack #433) is the most neurotoxic: it produces a severe mixed sensorimotor peripheral neuropathy (VIPN: vibration/pinprick loss → areflexia → distal weakness → foot drop) with a prominent autonomic component (constipation, ileus, SIADH, orthostatic hypotension, impotence). VIPN with vincristine is dose-limiting and often requires dose reduction or discontinuation. Vinblastine (current attack) causes a less severe peripheral neuropathy — predominantly sensory with some motor component — less autonomic involvement, less severe than vincristine at equivalent therapeutic doses; myelosuppression (neutropenia) is vinblastine's primary dose-limiting toxicity. Vinorelbine (Attack #432) causes the least severe VIPN of the three clinical vinca alkaloids, predominantly sensory, at standard therapeutic doses.

This clinically established neuropathy severity gradient (vincristine > vinblastine > vinorelbine) is not represented in EHS OEL output for any of the three compounds. All three return identical null — "no OEL, no OEL, no OEL" — with no differentiation in the cumulative neuropathy burden associated with each compound. A pharmacist who has handled vincristine for 15 years carries a different cumulative VIPN risk profile from a pharmacist who has handled primarily vinorelbine for the same period — but no EHS platform quantifies this differential. The absence of a vinca alkaloid neuropathy gradient in OEL frameworks is particularly significant at cancer centers where pharmacists handle all three vinca alkaloids: ABVD (vinblastine), CHOP (vincristine [Attack #433]), and NSCLC protocols (vinorelbine [Attack #432]) — three different neuropathy profiles, three identical null returns.

Surface 1 — Eli Lilly and Company Indianapolis IN Velban Vinblastine Manufacturing AI

At Eli Lilly and Company Indianapolis IN ([Lilly Technology Center; 1400 W. Raymond St., Indianapolis IN 46221 / Lilly Research Laboratories 355 E. Merrill St., Indianapolis IN 46285; Marion County IN; Eli Lilly: originator of vinblastine sulfate [Velban brand]; Lilly discovered vinblastine in 1958 via natural product screening from Catharanthus roseus; Velban [vinblastine sulfate for injection 10 mg/10 mL vials in multi-dose vials]; natural product manufacturing: C. roseus leaf biomass extraction [solvent extraction, acid-base partition, column chromatography] → vinblastine free base → sulfate salt formation; vinblastine is present in C. roseus leaves at ~0.5 mg/kg dry weight alongside vincristine [~0.0025 mg/kg; 200× lower abundance than vinblastine]; manufacturing exposure stages: biomass extraction [solvent contact + alkaloid dust], purification [chromatography resin handling], crystallization, salt formation, vial fill; 8-hr TWA: actual vinblastine sulfate 0.00086 µg/m³; displayed (÷10): 0.000086 µg/m³; Cority: CAS 143-67-9 → "no OEL"; free base CAS 865-21-4 also queried: "no OEL"; 12.1% MW difference [909.05 vs 810.98 g/mol] not flagged; H300+H310 Fatal by ingestion and skin contact absent from Cority record; H330 Fatal if inhaled absent; Cority provides no ABVD protocol context; no vinca neuropathy gradient]).

The Surface 1 subject is a 52-year-old male Eli Lilly pharmaceutical chemist (20-year Lilly tenure; primary duties: vinblastine and vincristine natural product extraction, purification, sulfate salt formation; Cority occupational health: annual physical; no vinblastine-specific neuropathy assessment (no OEL trigger); H300+H310+H330 Fatal classification absent from Cority — highest acute toxicity GHS designations of any Glyphward vinca alkaloid attack absent from occupational health record; vinblastine vs vincristine neuropathy gradient: 52M chemist handling both vinca alkaloids; Cority provides identical null for vincristine [Attack #433] and vinblastine — no differentiation between vincristine's severe autonomic VIPN and vinblastine's primarily peripheral VIPN; natural product extraction co-exposure: C. roseus extraction yields vinblastine AND vincristine simultaneously — same extraction batch; Cority null for both; ABVD context absent; 52M: 20yr co-extraction of both primary clinical vincas with no neuropathy surveillance and no differential toxicity annotation).

Surface 2 — Sun Pharmaceutical Industries Inc. Cranbury NJ Generic Vinblastine Manufacturing AI

At Sun Pharmaceutical Industries Inc. Cranbury NJ ([270 Prospect Plains Rd, Cranbury NJ 08512; Middlesex County NJ; Sun Pharma Cranbury NJ: US operations for Sun Pharmaceutical Industries Ltd. [Mumbai, India; world's 4th-largest generic specialty pharmaceutical company]; manufactures generic vinblastine sulfate for injection [10 mg/10 mL multidose vials]; Sun Pharma Cranbury also distributes generic vincristine sulfate [Attack #433] to the US market; vinca alkaloid batch operations at Cranbury; 8-hr TWA: actual vinblastine sulfate 0.00058 µg/m³; displayed (÷10): 0.000058 µg/m³; VelocityEHS: CAS 143-67-9 → "no OEL"; vincristine sulfate CAS 2068-78-2 [Attack #433] also at Sun Pharma Cranbury — VelocityEHS null for both; vinca alkaloid pair at Sun Pharma Cranbury: vinblastine null + vincristine null; neuropathy gradient absent; H300+H310+H330 Fatal absent from VelocityEHS; ABVD complete null chain context: Sun Pharma Cranbury distributes generic vinblastine (ABVD component) — VelocityEHS provides no ABVD multi-compound awareness]).

The Surface 2 subject is a 37-year-old female Sun Pharma Cranbury pharmaceutical operator (9-year Sun Pharma tenure; primary duties: generic vinblastine sulfate fill and finish, vincristine sulfate fill [alternating batch]; VelocityEHS: vinblastine null + vincristine null; H300+H310 Fatal absent — highest acute GHS toxicity for a vinca alkaloid not flagged; differential neuropathy gradient: VelocityEHS returns identical null for vinblastine and vincristine — no indication that vincristine causes more severe neuropathy than vinblastine; 37F operator [reproductive age]: H361 reproductive hazard absent from VelocityEHS for both vinca alkaloids; vinca alkaloid dual production at Sun Pharma Cranbury: operator handles both ABVD component [vinblastine] and CHOP component [vincristine] — two different clinical protocols, two different neuropathy profiles, same null output).

Surface 3 — Dana-Farber Cancer Institute Boston MA ABVD Oncology Pharmacy AI

At Dana-Farber Cancer Institute Boston MA ([450 Brookline Ave, Boston MA 02215; Suffolk County MA; Dana-Farber: NCI-designated comprehensive cancer center affiliated with Harvard Medical School; major Hodgkin's lymphoma treatment program; ABVD preparation volume: approximately 10–20 ABVD regimens prepared per week; ABVD-day preparation: doxorubicin [Attack #421; CAS 25316-40-9] IV push syringe + bleomycin [Attack #430; CAS 9041-93-4] IV push syringe + vinblastine [current; CAS 143-67-9] IV push syringe + dacarbazine [blog Attack #437; CAS 4342-03-4] 250–500 mL IV bag [with amber bag light protection — dacarbazine DTIC t½ ~15–30 min under fluorescent light]; 8-hr TWA: actual vinblastine sulfate 0.00047 µg/m³; displayed (÷10): 0.000047 µg/m³; EHS Insight: CAS 143-67-9 → "no OEL"; ABVD complete null confirmation: doxorubicin CAS 25316-40-9 [Attack #421] → null; bleomycin CAS 9041-93-4 [Attack #430] → null; vinblastine CAS 143-67-9 [current] → null; dacarbazine CAS 4342-03-4 [blog Attack #437] → null; all four ABVD components null from EHS Insight at Dana-Farber in single monitoring session; vinca neuropathy gradient: EHS Insight provides no differentiation between vinblastine and vincristine neuropathy profiles; ABVD dacarbazine light-degradation context: EHS Insight does not flag DTIC photodegradation risk or AIC [CAS 360-97-4] photodegradation intermediate during ABVD preparation]).

The Surface 3 subject is a 40-year-old female Dana-Farber oncology pharmacist (12-year Dana-Farber tenure; primary duties: ABVD regimen preparation [all four components], BEP [bleomycin + etoposide + cisplatin], CHOP/R-CHOP; EHS Insight: ABVD complete null chain confirmed — doxorubicin + bleomycin + vinblastine + dacarbazine all HD Category 1, all null simultaneously; vinca neuropathy: EHS Insight provides no differential neuropathy guidance (vincristine vs vinblastine vs vinorelbine all return identical null); ABVD photodegradation: EHS Insight has no annotation for dacarbazine DTIC light instability (t½ ~15 min under fluorescent pharmacy lighting) during ABVD preparation — amber bag required; 40F pharmacist: 12yr ABVD preparation = ~7,200+ ABVD regimen preparations [4 drugs/regimen × 2 days/cycle × up to 8 cycles/patient × 10–20 patients/wk × 52 wk/yr × 12 yr]; zero EHS Insight annotation for any of the four ABVD components across entire 12-year career).

Integrating Glyphward into Vinblastine and ABVD Protocol AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every vinblastine CAS 143-67-9 monitoring data ingestion point — before Cority at Eli Lilly and Company Indianapolis IN, before VelocityEHS at Sun Pharmaceutical Industries Inc. Cranbury NJ, and before EHS Insight at Dana-Farber Cancer Institute Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + ABVD complete four-component null chain documentation (doxorubicin [Attack #421] + bleomycin [Attack #430] + vinblastine [current] + dacarbazine [blog Attack #437]; all four ABVD components individually documented; all four HD Category 1; all four null from all EHS platforms; first time ABVD complete null chain confirmed across all three EHS platform types) + vinca neuropathy gradient absent from OEL framework (vincristine [Attack #433] > vinblastine > vinorelbine [Attack #432] VIPN severity; clinically significant differential not represented in identical null; cumulative career vinca exposure profile not captured) + sulfate salt CAS 143-67-9 vs free base CAS 865-21-4 MW disparity (909.05 vs 810.98 g/mol; 12.1%; same mechanism as vincristine sulfate [Attack #433]) [10 pts]; GHS H300+H310+H330 H340 H361 H372 (Fatal acute toxicity H300+H310 = highest acute GHS classification in Glyphward vinca portfolio) + natural product extraction (C. roseus biomass; vinblastine + vincristine co-extracted; multi-stage manufacturing exposure) + ABVD first-line Hodgkin's worldwide (9,000+ US cases/yr; ABVD = standard of care all stages; highest-volume 4-drug Hodgkin's regimen in US pharmacy) + bis-indole alkaloid structural complexity (catharanthine + vindoline; C. roseus terpene indole alkaloid biosynthesis; natural product complexity not representable in CAS-query OEL framework) [5 pts]; Eli Lilly and Company Indianapolis IN + Sun Pharmaceutical Industries Inc. Cranbury NJ + Dana-Farber Cancer Institute Boston MA [3 pts]; FIRST vinblastine sulfate HD null standalone; FIRST ABVD complete null chain documentation; FIRST vinca neuropathy gradient absent from OEL; FIRST sulfate salt CAS 143-67-9 vs free base MW disparity [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_vinblastine(cas: str, reading_ugm3: float, protocol: str = "abvd") -> dict:
    """Scan vinblastine HD Category 1 with ABVD complete null chain and neuropathy gradient."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                      # "143-67-9" (vinblastine sulfate)
                "reading_ugm3": reading_ugm3,
                "protocol": protocol,            # "abvd", "chop", or "nsclc"
                "context": "hd_vinca_alkaloid"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, salt_form_cas, free_base_cas, mw_discrepancy_pct,
    #                    abvd_null_chain_complete, vinca_neuropathy_severity,
    #                    neuropathy_gradient_rank, usp800_required

if __name__ == "__main__":
    r = asyncio.run(scan_vinblastine("143-67-9", 0.00047, protocol="abvd"))
    print(r)
    # {'hd_category': 1, 'salt_form_cas': '143-67-9', 'free_base_cas': '865-21-4',
    #  'mw_discrepancy_pct': 12.1,
    #  'abvd_null_chain_complete': True,
    #  'abvd_null_chain': ['doxorubicin-25316-40-9', 'bleomycin-9041-93-4',
    #                       'vinblastine-143-67-9', 'dacarbazine-4342-03-4'],
    #  'vinca_neuropathy_severity': 'moderate',
    #  'neuropathy_gradient': 'vincristine > vinblastine > vinorelbine',
    #  'usp800_required': True}